Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors.
Marta García-LópezGrupo de Investigación Traslacional con Células iPS, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), 28041 Madrid, Spain.
Lydia Jiménez-VicenteGrupo de Investigación Traslacional con Células iPS, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), 28041 Madrid, Spain.ORCID 0009-0002-2494-7445
Raquel González-JabardoGrupo de Investigación Traslacional con Células iPS, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), 28041 Madrid, Spain.ORCID 0009-0003-2286-5785
Helena DoradoGrupo de Investigación Traslacional con Células iPS, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), 28041 Madrid, Spain.ORCID 0009-0001-3158-004X
Irene Gómez-ManjónServicio de Genética, Hospital 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), 28041 Madrid, Spain.ORCID 0000-0001-7137-1915
Miguel Ángel MartínServicio de Genética, Hospital 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), 28041 Madrid, Spain.ORCID 0000-0003-4741-772X
Carmen AyusoCentro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28029 Madrid, Spain.ORCID 0000-0002-9242-7065
Joaquín ArenasLaboratorio de Enfermedades Mitocondriales y Neuromusculares, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), 28041 Madrid, Spain.
María Esther GallardoGrupo de Investigación Traslacional con Células iPS, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), 28041 Madrid, Spain.ORCID 0000-0002-8699-8734
Funding
Agencia Estatal de Investigación PCI2022-132920European Regional Development Fund PI15/00484, CP16/00046, and PI18/00151European Union PI21/00162 and CPII21/00011Instituto de Salud Carlos III PI15/00484, CP16/00046, PI18/00151 PI21/00162, CPII21/00011, FI19/00043Organización Nacional de Ciegos Españoles 2021/0146; 2022/0152; 2023/0121
6 · The paper itself
Abstract
Autosomal dominant optic atrophy (ADOA) is a rare progressive disease mainly caused by mutations in
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Creation of an Isogenic Human iPSC-Based RGC Model of Dominant Optic Atrophy Harboring the Pathogenic Variant c.1861C>T (p.Gln621Ter) in the · full record | Socratic